Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $45.14 Average Price Target from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $45.1429.

ORKA has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research report on Thursday, November 13th. They set a “buy” rating and a $45.00 price target for the company. HC Wainwright dropped their price objective on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Barclays assumed coverage on Oruka Therapeutics in a report on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective for the company. BTIG Research boosted their target price on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Guggenheim began coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They set a “buy” rating and a $60.00 price target on the stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the third quarter worth approximately $39,000. Russell Investments Group Ltd. acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $43,000. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $31,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Down 0.1%

Shares of ORKA stock opened at $30.18 on Friday. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $32.28. The firm’s fifty day moving average price is $27.78 and its two-hundred day moving average price is $19.00. The firm has a market capitalization of $1.46 billion, a P/E ratio of -15.88 and a beta of -0.41.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. As a group, equities research analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.